Human epidermal growth factor receptor 2 (HER2)-positive breast cancer accounts for approximately 20-30% of total breast cancer cases and is associated with inferior prognosis compared to HER2-negative subtypes [1–5]. The gene discussed is ERBB2; the disease is breast carcinoma.